

Baxter International Inc.

U.S. Securities Litigation

Baxter International Inc. (NYSE: BAX): Baxter International Inc. ("Baxter" or the "Company") and certain of the Company's senior executives have been sued for violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Baxter common stock. The case is pending in the U.S. District Court for the Northern District of Illinois and is captioned *Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al.*, No. 1:25-cv-12672.

If you incurred losses on your investments in Baxter, you are encouraged to submit your information.

Why Was Baxter Sued for Securities Fraud?

Baxter manufactures medical devices. One of the Company's most important growth drivers is its Novum IQ Large Volume pump ("Novum LVP"), a medical device that intravenously delivers medications, blood products, and nutrients to patients. In 2020, Baxter launched the Novum LVP in Canada while its application for FDA approval in the U.S. was pending. After the Canada launch, serious malfunctions such as under-and over-medicating patients plagued the pumps.

During the relevant period, Baxter told investors that the Novum LVP had "the most advanced safety features that are available," stated the pump would provide "a safer delivery of medication to the patient," and insisted that the "rollout in Canada" provided "a lot of opportunity to just work out any last kind of bugs and kinks." Indeed, Baxter described the U.S. rollout, which began in April 2024, as "a resounding success."

As alleged, in truth, the Novum LVP suffered from systemic defects that caused a variety of malfunctions such as under-infusion, over-infusion, and non-delivery of fluids which put patient safety at risk and caused significant injuries and multiple fatalities.

The Stock Declines as the Truth Is Revealed

On July 31, 2025, Baxter announced that it had decided to “voluntarily and temporarily pause shipments and planned installations of the Novum LVP” and was “unable to currently commit to an exact timing for resuming shipment and installation.” On this news, the price of Baxter stock fell \$6.29 per share, or more than 22%, from \$28.05 per share on July 30, 2025, to \$21.76 per share on July 31, 2025.

What Are My Rights?

If you purchased or otherwise acquired Baxter stock, you may ask the Court no later than December 15, 2025, which is the first business day after 60 days from the date of the publication of notice of pendency of the action, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

Contact Us

If you incurred losses on your investments in Baxter, you are encouraged to submit your information to speak with an attorney about your rights.

You can also contact:

Ross Shikowitz

ross@bfalaw.com

212.789.3619

All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*, and its attorneys have been named “Elite Trial Lawyers” by the *National Law Journal*, among the top “500 Leading Plaintiff Financial Lawyers” by *Lawdragon*, “Titans of the Plaintiffs’ Bar” by *Law360* and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over \$900 million in value

from Tesla, Inc.'s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.